Expertise in
8
conditions

Dr. Anca D. Askanase

Rheumatology
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 
Offers Telehealth
Expertise in
8
conditions
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 

Overview

Anca Askanase is a Rheumatologist in New York, New York. Dr. Askanase is highly rated in 8 conditions, according to our data. Her top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Undifferentiated Connective Tissue Disease (UCTD), and Cutaneous Lupus Erythematosus (CLE).

Her clinical research consists of co-authoring 173 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Internal Medicine in NY

Hospital Affiliations

New York-Presbyterian Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
161 Fort Washington Ave, New York, NY 10032
Other Locations
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
622 W 168th St, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.
Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: CellCept, ACTHar Gel
Study Phase: Phase 4
Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Enrollment Status: Terminated
Publish Date: February 27, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 18, 2022
Intervention Type: Drug
Study Drug: JBT-101
Study Phase: Phase 2
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Enrollment Status: Completed
Publish Date: December 01, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

173 Total Publications

Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.
Journal: JCI insight
Published: November 25, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Robert F. Spiera
Rheumatology
Expertise in
19
conditions
Dr. Robert F. Spiera
Rheumatology

HSS - Belaire Building

525 East 71st Street, 7th Floor, 
New York, NY 
 (5.2 miles away)
212-860-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Spiera is a Rheumatologist in New York, New York. Dr. Spiera is highly rated in 19 conditions, according to our data. His top areas of expertise are Systemic Sclerosis (SSc), Vasculitis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica. Dr. Spiera is currently accepting new patients.

Expertise in
35
conditions
Dr. Alice Gottlieb
Rheumatology
Expertise in
35
conditions
Dr. Alice Gottlieb
Rheumatology

Gramercy Park Physicians LLP

10 Union Sq E, 
New York, NY 
 (7.7 miles away)
212-844-8800
Languages Spoken:
English
See accepted insurances

Alice Gottlieb is a Rheumatologist in New York, New York. Dr. Gottlieb is highly rated in 35 conditions, according to our data. Her top areas of expertise are Psoriasis, Plaque Psoriasis, Generalized Pustular Psoriasis (GPP), and Hidradenitis Suppurativa.

Expertise in
20
conditions
Dr. Lindsay Lally
Rheumatology
Expertise in
20
conditions
Dr. Lindsay Lally
Rheumatology

Belaire Building

525 E 71st St Fl 7, 
New York, NY 
 (5.0 miles away)
212-774-2434
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lindsay Lally is a Rheumatologist in New York, New York. Dr. Lally has been practicing medicine for over 18 years is highly rated in 20 conditions, according to our data. Her top areas of expertise are Rhizomelic Pseudopolyarthritis, Polymyalgia Rheumatica, Temporal Arteritis, and Giant Cell Arteritis (GCA).

Frequently Asked Questions about Dr. Anca D. Askanase

How do I make an appointment with Dr. Anca D. Askanase?

You can book an appointment with Dr. Anca D. Askanase by calling their office at 212-305-3870. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anca D. Askanase a top-rated expert for Systemic Lupus Erythematosus (SLE)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anca D. Askanase is classified as an Elite expert for Systemic Lupus Erythematosus (SLE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anca D. Askanase specialize in?

While Dr. Anca D. Askanase is a Rheumatology, they have specific expertise in Systemic Lupus Erythematosus (SLE), Lupus Nephritis, and Undifferentiated Connective Tissue Disease (UCTD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Anca D. Askanase participate in research or clinical trials?

Yes. Dr. Anca D. Askanase has published 173 articles and abstracts on conditions like Systemic Lupus Erythematosus (SLE). You can view a list of Dr. Anca D. Askanase's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anca D. Askanase accept my insurance?

Dr. Anca D. Askanase accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 212-305-3870 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Askanase's expertise for a condition
ConditionClose
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile